Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: Subgroup analysis of a randomized phase 3 trial

  1. Zinzani, P.L.
  2. Khuageva, N.K.
  3. Wang, H.
  4. Garicochea, B.
  5. Walewski, J.
  6. Van Hoof, A.
  7. Soubeyran, P.
  8. Caballero, D.
  9. Buckstein, R.
  10. Esseltine, D.-L.
  11. Theocharous, P.
  12. Enny, C.
  13. Zhu, E.
  14. Elsayed, Y.A.
  15. Coiffier, B.
Aldizkaria:
Journal of Hematology and Oncology

ISSN: 1756-8722

Argitalpen urtea: 2012

Alea: 5

Mota: Artikulua

DOI: 10.1186/1756-8722-5-67 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus